Jazz Pharmaceuticals
JAZZ
471 hedge funds and large institutions have $8.31B invested in Jazz Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 58 funds opening new positions, 168 increasing their positions, 154 reducing their positions, and 64 closing their positions.
80% more call options, than puts
Call options by funds: $14.8M | Put options by funds: $8.22M
1.2% more ownership
Funds ownership: 89.26% → 90.46% (+1.2%)
9% more repeat investments, than reductions
Existing positions increased: 168 | Existing positions reduced: 154
9% less first-time investments, than exits
New positions opened: 58 | Existing positions closed: 64
3% less funds holding
Funds holding: 486 → 471 (-15)
6% less capital invested
Capital invested by funds: $8.82B → $8.31B (-$513M)
38% less funds holding in top 10
Funds holding in top 10: 8 → 5 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Swedbank
Stockholm,
Sweden
|
+$114M |
| 2 |
Millennium Management
New York
|
+$106M |
| 3 |
BG
Baupost Group
Boston,
Massachusetts
|
+$70.8M |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
+$68.5M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$48.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$107M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$61.3M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$61.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$52.6M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$29.5M |
JAZZ Hedge Fund Activity: Q1 2023 in Review
471 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q1 2023, worth a combined $8.31B — down 5.8% from $8.82B a quarter earlier.
Sellers outnumbered buyers: 64 funds closed out of JAZZ and 58 opened new positions — a net loss of 6 holders — while 154 trimmed existing stakes and 168 added.
The largest buyer was Swedbank, adding an estimated $114M. The largest seller was JP Morgan Chase, cutting an estimated $107M.
- 471 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q1 2023, down from 486 in Q4 2022.
- Funds reported $8.31B of Jazz Pharmaceuticals stock for Q1 2023, down 5.8% quarter-over-quarter.
- 58 funds opened new Jazz Pharmaceuticals positions in Q1 2023 and 64 closed out, a net change of -6 holders.
- The largest Jazz Pharmaceuticals buyer in Q1 2023 was Swedbank, an estimated $114M added.
- The largest Jazz Pharmaceuticals seller in Q1 2023 was JP Morgan Chase, an estimated $107M sold.
Based on aggregated 13F filings for Q1 2023.